Risk factors for nephropathy in type 2 diabetes mellitus
Tóm tắt
Từ khóa
Tài liệu tham khảo
Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010.Diabet Med. 1997;14(suppl 5):S1–85.
Parving H-H, Osterby R, Anderson PW, Hsueh WA. Diabetic nephropathy. In: Brenner BM, ed.The Kidney. 5th ed. Philadelphia: Saunders; 1996:1864–1892.
Agewall S, Wikstrand J, Ljungman S, Fagerberg B. Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus.Am J Cardiol. 1997;80:164–169.
Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia.Arch Int Med. 1998;158:998–1004.
Gall M-A, Hougaard P, Borch-Johnsen K, Parving H-H. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study.BMJ. 1997;314:783–788.
Tatti P, Pahor M, Byington RP, Di Mauro P, Guartisco R, Strollo F. Results of the Fosinopril Amlodipine Cardiovascular Events Trial (FACET) in hypertensive patients with non-insulin dependent diabetes mellitus (NIDDM).Diabetes Care. 1998;21:655–657.
Byington RP, Craven T, Furberg CD, Pahor M. Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events.Lancet. 1997;350:1075–1076.
Schrier RW, Estacio RO, Jeffers B. Appropriate blood pressure control in NIDDM.Diabetologia. 1996;39(12):1646–1654.
Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial.Lancet. 1998;351:1755–1762.
Gall M-A, Rossing P, Skott P, Damsbo P, Vaag A, Bech K, et al. Prevalence of micro-and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin dependent) diabetic patients.Diabetologia. 1991;34:655–661.
Bianchi S, Bigazzi R, Campese V. Microalbuminuria in essential hypertension.J Nephrol. 1997;10(4):216–219.
Bigazzi R, Bianchi S, Baldari D, Campese V. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension.J Hypertension. 1998;16:1325–1333.
Moorhead JF, El-Nahas M, Chan MK, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease.Lancet. 1982;2:1309–1311.
Ravid M, Neumann L, Lishner M. Plasma lipids and the progression of nephropaty in diabetes mellitus type 2: effect of ACE inhibitors.Kidney Int. 1995;47:907–910.
Nelson RG, Knowler WC, Pettitt DJ, Hanson RL, Benett PH. Incidence and determinants of elevated urinary albumin excretion in Pima Indians with NIDDM.Diabetes Care. 1995;18:182–187.
Parving H-H. Renoprotection in diabetes: genetic and nongenetic risk factors and treatment.Diabetologia. 1998;41:745–759.
Ravid M, Rachmani R. Cholesterol as a predictor of diabetic renal disease. In: Kean WF, Horl W, Kasiske BL, eds.Lipids and the Kidney. Basel: S. Karger AG; 1997;39–47.
Hommel E, Andersen P, Gall M-A, Nielsen F, Jensen B, Rossing P, et al. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy.Diabetologia. 1992;35:447–451.
Lam KS, Cheng IKP, Janus ED, Pang RWC. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy.Diabetologia. 1995;38:604–609.
Nielsen J, Schmitz O, Moller N, Porksen N, Klausen IC, Alberti KG, et al. Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin dependent) diabetic patients with microalbuminuria.Diabetologia. 1993;36:1079–1086.
Diabetes Control and Complications (DCCT) research group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the diabetes control and complications trial.Kidney Int. 1995;47:907–910.
Gall M-A, Nielsen FS, Smidt UM, Parving H-H. The course of kidney function in type 2 (non-insulin dependent) diabetic patients with diabetic nephropathy.Diabetologia. 1993;36:1071–1078.
Biesenbach G, Janko O, Zazgornic J. Similar rate of progression in predialysis phase in type I and type II diabetes mellitus.Nephrol Dial Transplant. 1994;9:1097–1102.
Wu H, Yu C, Yang C-W, Wu CH, Haung JY, Hong JJ, et al. Poor pre-dialysis glycaemic control is a predictor of mortality in type 2 diabetic patients on maintenance haemodyialisis.Nephrol Dial Transplant. 1997;12:2105–2110.
United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).Lancet. 1998;152:837–853.
Mogensen CE. Long term antihypertensive treatment inhibiting progression of diabetic nephropathy.BMJ. 1982;285:256–264.
Taft JL, Nolan CJ, Yeung SP, Hewitson TD, Martin FIR. Clinical and histological correlation of decline in renal function in diabetic patients with proteinuria.Diabetes. 1994;43:1046–1051.
Breyer JA, Bain RP, Evans JK, Nahman NS, Lewis EJ, Cooper M, et al. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy.Kidney Int. 1996;50:1651–1658.
Yokoama H, Tomonaga D, Hirayama M, Ishii A, Takeda M, Babazono T, et al. Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in IDDM patients.Diabetologia. 1997;40:405–411.
Ravid M, Savin H, Lang R, Jutrin I, Shoshana L, Lishner M. Proteinuria, renal impairment, metabolic control and blood pressure in type 2 diabetes mellitus.Arch Int Med. 1992;152:1225–1229.